Keynote Financial Services LLC Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Keynote Financial Services LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,885 shares of the company’s stock after purchasing an additional 110 shares during the quarter. Eli Lilly and Company comprises 1.1% of Keynote Financial Services LLC’s portfolio, making the stock its 22nd biggest holding. Keynote Financial Services LLC’s holdings in Eli Lilly and Company were worth $1,455,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Values Added Financial LLC lifted its holdings in Eli Lilly and Company by 4.9% in the 3rd quarter. Values Added Financial LLC now owns 366 shares of the company’s stock valued at $324,000 after purchasing an additional 17 shares in the last quarter. Pursue Wealth Partners LLC purchased a new position in shares of Eli Lilly and Company in the 3rd quarter worth about $364,000. Creative Financial Designs Inc. ADV grew its stake in Eli Lilly and Company by 2.0% during the third quarter. Creative Financial Designs Inc. ADV now owns 16,339 shares of the company’s stock worth $14,475,000 after buying an additional 325 shares during the period. Lebenthal Global Advisors LLC lifted its stake in shares of Eli Lilly and Company by 12.6% during the third quarter. Lebenthal Global Advisors LLC now owns 2,177 shares of the company’s stock worth $1,929,000 after purchasing an additional 243 shares in the last quarter. Finally, Interchange Capital Partners LLC lifted its position in Eli Lilly and Company by 2.2% during the 3rd quarter. Interchange Capital Partners LLC now owns 1,061 shares of the company’s stock worth $940,000 after acquiring an additional 23 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on LLY shares. Wolfe Research initiated coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 target price on the stock. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a report on Thursday, January 16th. Citigroup reduced their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Finally, Truist Financial increased their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Three equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,000.28.

Eli Lilly and Company Stock Up 1.7 %

Shares of LLY stock opened at $920.44 on Friday. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The firm’s fifty day moving average price is $814.88 and its two-hundred day moving average price is $848.69. The firm has a market capitalization of $872.73 billion, a P/E ratio of 78.60, a PEG ratio of 1.40 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has initiated a stock buyback program on Monday, December 9th that authorizes the company to buyback $15.00 billion in shares. This buyback authorization authorizes the company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s payout ratio is presently 51.24%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.